Enavate Sciences Backs Graviton Bioscience in Financing Round to Advance Development of Selective ROCK2 Inhibitors streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced separate collaborations with.
Exact Sciences Completes Acquisition of Ashion Analytics, LLC, from The Translational Genomics Research Institute, an affiliate of City of Hope
Talented team and industry-leading lab will help strengthen the company s sequencing and pipeline capabilities, while broadening its therapy selection and treatment guidance offerings
News provided by
Share this article
(PRNewsfoto/EXACT SCIENCES CORP)
(PRNewsfoto/EXACT SCIENCES CORP)
MADISON, Wis., April 14, 2021 /PRNewswire/ Exact Sciences Corp. (NASDAQ: EXAS) today announced that it has completed its previously announced acquisition of Ashion Analytics, LLC. As a leader in cancer testing, we re committed to providing earlier answers and life-changing treatment guidance to support patients along every step of their cancer journey, said Kevin Conroy, chairman and CEO of Exact Sciences. With Ashion, we ve added a talented team, a CLIA-certified and CAP-accredited lab, deep sequencing capabilities, and one of the most comprehensiv
Exact Sciences to Acquire Ashion Analytics and Enter Research Collaboration with City of Hope s Genomics Institute, TGen
Provides Access to Industry-Leading Sequencing Lab and Plans for 10-Year Partnership with National Cancer Research Leaders
News provided by
Share this article
(PRNewsfoto/EXACT SCIENCES CORP)
(PRNewsfoto/EXACT SCIENCES CORP)
MADISON, Wis., Feb. 16, 2021 /PRNewswire/ Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has entered into an agreement to acquire Ashion Analytics, LLC (Ashion) from The Translational Genomics Research Institute (TGen), an affiliate of City of Hope. Ashion is a CLIA-certified and CAP-accredited sequencing lab based in Phoenix, Arizona with the genomics testing capabilities necessary to address the increasingly complex needs of clinical, academic, and biopharma customers focused on precision cancer treatments. The team at Ashion will help accelerate the development of Exact Sciences precision oncology portfolio, including
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology from the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. This compelling and technically distinct approach will help expand Exact Sciences leadership in precision oncology and offers a differentiated patient-specific solution in minimal residual disease testing.